Enteris BioPharma Highlighted as Game Changer in Drug Development & Delivery Special Feature on Innovative Technologies for Improving Drug Solubility and Bioavailability
Boonton, NJ – April 4, 2022 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), announced today that CEO, Rajiv Khosla, Ph.D., was featured in Drug Development and Delivery discussing the ability of Enteris’ Peptelligence® and ProPerma® technologies to overcome the permeability and solubility issues that prevent the oral delivery of many “beyond the rule of 5” (bRo5) compounds, including peptides, peptidomimetics, and intermediate-sized small molecule compounds.
READ FULL PRESS RELEASE
Meet Enteris Biopharma at CPhI North America 2022
May 17-19, Philadelphia, PA
To learn more about our technologies and CMO service offerings please fill out and submit the form.